GlassScriptPhysician profile
Frederick Niegos
NPI 1649277401
$6,913.84
in general payments reported to CMS, 2019-2025
36 companies · $587 in 2025
The $587 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,746 · 2020: $1,239 · 2021: $577 · 2022: $1,017 · 2023: $1,144 · 2024: $604 · 2025: $587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,335.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,198.18 | 2019-2025 | Ozempic, Rybelsus, Sogroya |
| Amgen INC. | $745.61 | 2019-2025 | Prolia, Evenity, Tepezza |
| Medtronic, INC. | $624.90 | 2022-2025 | Minimed 780g, Minimed 770g |
| Lilly USA, LLC | $614.59 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $354.38 | 2019-2024 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $295.94 | 2019-2022 | |
| Amarin Pharma, INC. | $294.98 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $282.07 | 2019-2025 | |
| Abbott Laboratories | $261.68 | 2019-2025 | Freestyle Libre 3 |
| Medtronic Minimed, INC. | $254.17 | 2019-2020 | |
| Tandem Diabetes Care, INC. | $201.27 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Horizon Therapeutics Plc | $172.44 | 2022-2023 | Tepezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.73 | 2019-2021 | |
| Mannkind Corporation | $141.02 | 2023 | Afrezza |
| Abbvie INC. | $140.80 | 2019-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $128.27 | 2019-2023 | |
| Ascensia Diabetes Care US INC. | $127.53 | 2024 | |
| Ascendis Pharma Endocrinology INC | $122.55 | 2023 | |
| Recordati_rare_diseases_inc. | $100.70 | 2022-2025 | Isturisa, Signifor Lar |
| Averitas Pharma INC. | $98.47 | 2023-2025 | Qutenza |
| Shire North American Group INC | $93.00 | 2019 | |
| Ibsa Pharma INC. | $83.24 | 2019-2021 | |
| Valeritas, INC. | $67.63 | 2019 | |
| Merck Sharp & Dohme LLC | $63.74 | 2019-2020 | |
| Corcept Therapeutics | $45.94 | 2020-2023 | Korlym |
| Janssen Pharmaceuticals, INC | $42.52 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $29.89 | 2022-2024 | Gvoke Hypopen |
| Beta Bionics, INC. | $22.34 | 2024 | Ilet Bionic Pancreas |
| Vivus LLC | $22.10 | 2024 | Qsymia |
| Eusa Pharma (US) LLC | $21.84 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.61 | 2023 | |
| Kyowa Kirin, INC. | $20.13 | 2023 | Crysvita |
| Ultragenyx Pharmaceutical INC. | $18.79 | 2020 | |
| Pfizer INC. | $17.67 | 2023 | |
| Novartis Pharmaceuticals Corporation | $13.82 | 2025 | |
| Endo Pharmaceuticals INC. | $11.30 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Niegos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.